AIX 9.01 ▲0.33% ALU 0.88 ▼-2.22% DN1 99.70 ▼-0.09% EMUCA 0.89 KIT 1.90 ▲0.00% KKC 2.11 ▲0.00% LF1 1.92 ▲0.79% MBG 0.14 ▲0.00% MRE 1.88 ▼-0.53% PCI 1.09 ▼-0.91% PCX 1.99 ▼-0.75% RF1 3.52 ▼-0.28% SET 2.14 ▼-0.47% BST 0.30 ▲3.45% CTS 0.56 ▲1.82% EFR 0.00 ▲0.00% FDC 3.33 ▼-1.19% KOA 3.10 ▲1.64% AIX 9.01 ▲0.33% ALU 0.88 ▼-2.22% DN1 99.70 ▼-0.09% EMUCA 0.89 KIT 1.90 ▲0.00% KKC 2.11 ▲0.00% LF1 1.92 ▲0.79% MBG 0.14 ▲0.00% MRE 1.88 ▼-0.53% PCI 1.09 ▼-0.91% PCX 1.99 ▼-0.75% RF1 3.52 ▼-0.28% SET 2.14 ▼-0.47% BST 0.30 ▲3.45% CTS 0.56 ▲1.82% EFR 0.00 ▲0.00% FDC 3.33 ▼-1.19% KOA 3.10 ▲1.64%

CTE Cryosite Limited

Healthcare · Diagnostics & Research · website · 25 employees
$1.20
52wk 0.66 – 1.31
Overall
Value
Growth
Health
Quality
Momentum
Dividend
Price
About Cryosite Limited

Cryosite Limited provides outsourced clinical trials logistic services in Australia. It operates through Ambient, cold, and frozen; Ultra-frozen and cryogenic; and Cord Blood segments. The Ambient, cold, and frozen segment provides good manufacturing practice (GMP) clinical trial materials, scheduled medicines, controlled drug storage, clinical ancillary supplies, medical devices, and commercial products with strict temperature requirements. The Ultra-frozen and cryogenic segment offers advanced therapy medicinal products (ATMPS), such as cell and gene therapies (CGT), cell therapies, mRNA-based medicines, biological samples, and research and development materials requiring high-integrity cold storage. The Cord Blood segment provides storage of cord blood cell and tissue samples for personal or directed therapeutic use by maintaining under validated chain-of-identity controls. It also offers reverse logistics services, secondary packaging, inventory management, and quality transportation and distribution solutions. Cryosite Limited was incorporated in 1999 and is based in South Granville, Australia.

Fundamental trends
Financial statements
Loading…
Key metrics
Market cap
$58.57M
P/E (trailing)
30.00
P/E (forward)
EPS (trailing)
0.04
Dividend yield
Payout ratio
0.0%
Beta
0.15
EV / EBITDA
18.84
Price / Book
16.22
ROE
88.8%
Operating margin
19.1%
Net margin
13.9%
Total cash
$2.54M
Total debt
$8.82M
Current ratio
0.58
Debt / Equity
2.44
Free cash flow
$-1.89M
Avg volume
4,196
Latest annual results (FY ending 30 Jun 2025)
  • Revenue$14.12M
  • Gross profit$8.89M
  • Operating income$2.50M
  • Net income$1.88M
  • Diluted EPS0.04
  • Free cash flow$1.48M
  • Net debt-$2.79M
Sector peers (Healthcare)
TickerMkt cap P/EScore
CSL $59.53B 14.0
RMD $43.89B 20.4
SIG $34.28B 59.4
FPH $20.25B 52.2
PME $17.21B 73.5
SHL $10.79B 19.7
RHC $10.13B 34.8
COH $7.90B 22.9